BIOORGANIC & MEDICINAL CHEMISTRY LETTERS《生物有机与药物化学快报》(可网站投稿)

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS《生物有机与药物化学快报》(半月刊). Bioorganic & Medicinal Chemistry Letters publishes research communications of outstanding significance and timeliness on topics at the interface of chemistry and biology, together with invited concise review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The journal continues to be a major forum for the first publication of new chemical entities prior to them entering clinical trials.

杂志简称:bioorg med chem lett
中文译名:《生物有机与药物化学快报》
收录属性:scie(2024版), 目次收录(知网),英文期刊,
自引率:4.30%
投稿方向:医学、chemistry, organic有机化学、chemistry, medicinal药物化学

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS《生物有机与药物化学快报》

SCI/E期刊基本信息

出版周期:半月刊 地区:英国
中科院分区:3区
是否TOP:非TOP期刊
是否综述:非综述期刊
是否OA:非OA期刊
国际标准刊号:ISSN 0960-894X;E-ISSN 1464-3405
杂志语言:英语
出版国家:英国

杂志官网 联系方式

出版地址:PERGAMON-ELSEVIER SCIENCE LTD,THE BOULEVARD,LANGFORD LANE,KIDLINGTON,OXFORD,ENGLAND,OX5 1GB
杂志邮箱:
投稿网址:https://www.editorialmanager.com/BMCL
杂志官方网址:https://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry-letters
出版商网址:http://www.elsevier.com

杂志投稿要求

投稿须知【杂志社官方网站信息】

Guide for Authors

Aims and scope

Bioorganic & Medicinal Chemistry Letters publishes research communications of outstanding significance and timeliness on topics at the interface of chemistry and biology, together with invited concise review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The journal continues to be a major forum for the first publication of new chemical entities prior to them entering clinical trials.

The Journal welcomes papers on:

the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targets

the reporting of the discovery, design or optimization of potent new compounds or biological agents

the analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental data

the reporting of "first-in-class" new therapeutic compounds

the chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanism

methodological advances that are chemistry-based and which significantly impact on medicine or biology

the preparation and examination of biotherapeutics for the treatment of pathophysiological disease states

the development of materials for specific therapeutic targeting

Manuscripts on phytochemistry, theoretical molecular dynamics and exclusively computational papers are out of scope. All manuscripts will be rigorously peer-reviewed by independent experts following an initial assessment by the Editors. Please note that BMCL is not suitable for straightforward reports of incremental advances. Above all the presentation of a rational basis and a sound underlying hypothesis for the work is of particular importance, whatever its exact field.

Bioorganic & Medicinal Chemistry Letters publishes research results of outstanding significance and timeliness in the fields of medicinal chemistry, chemical biology, bioorganic chemistry, bioinorganic chemistry, and related disciplines. Articles are in the form of communications reporting experimental or theoretical results of special interest. Hypothesis-driven theoretical studies containing complementary experimental reports are also welcome.

High-quality studies which are especially likely to meet these criteria, as compared to studies that simply report biological data for a series of newly-synthesised compounds. Examples include manuscripts

on the medicinal chemistry and associated biology of established or new disease targets, that report on potent new compounds and that analyse and discuss structure-activity relationships

on "first-in-class" new therapeutic compounds

on chemical biology, structural biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanism

on novel methodological advances that are chemistry-based and which significantly impact on medicine or biology

Above all the presentation of a rational, hypothesis-driven basis for the work is of particular importance, whether its exact field.

The journal wishes to encourage rapid communications of important new data, especially on novel potential drugs. Full analytical data is therefore not required on all compounds described in the text, but it is now required on lead compounds. Authors are welcome to provide such data on all reported compounds, should they so wish: this should be placed in a Supplementary Data section and made available to reviewers.

The journal will no longer accept routine studies on series of compounds that are straightforward extensions of existing knowledge. Phytochemical and purely computational studies are generally more appropriate for specialized journals.

BMCL is flexible and will consider Communications with a range of lengths, up to a maximum length of normally no more than 10 printed pages. Longer manuscripts or full papers may be more suited to the companion journal Bioorganic and Medicinal Chemistry.

Submission Checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

• E-mail address

• Full postal address

Email addresses for all authors should be supplied. Submission of a manuscript to BMCL is taken to mean that all authors are aware of, and agree to the submission.

All necessary files have been uploaded:

Manuscript:

• Include keywords

• All figures (include relevant captions)

• All tables (including titles, description, footnotes)

• Ensure all figure and table citations in the text match the files provided

• Indicate clearly if color should be used for any figures in print

• Include full synthetic and analytical data for lead compound(s)

• Include accession numbers for deposited crystal structures

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

• Manuscript has been 'spell checked' and 'grammar checked'

• All references mentioned in the Reference List are cited in the text, and vice versa

• Permission has been obtained for use of copyrighted material from other sources (including the Internet)

• A competing interests statement is provided, even if the authors have no competing interests to declare

• Journal policies detailed in this guide have been reviewed

• Referee suggestions and contact details provided, based on journal requirements. These suggestions may be used by the editors, at their discretion. Please do not name colleagues in your institution, or with whom you have a current or recent professional link.

刊知网 精心整理,转载请注明出处:https://www.kanzhiwang.com/archives/49841

我要点评 请您把投稿经验分享出来 让大家少走弯路少踩坑,我为人人、人人为我。

内容纠错 您如果发现杂志信息有错漏 可以在下方留言。

上一篇 2024年11月9日 下午12:53
下一篇 2024年11月9日 下午12:53

相关推荐

发表回复

登录后才能评论

联系我们

191 1833 1195

在线咨询: QQ交谈

邮件:321628655@qq.com

工作时间:周一至周五,9:30-18:30,节假日休息